UAB Hospital

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Retrieved on: 
Monday, January 8, 2024
Oncology, Health, Stem Cells, Neurology, Research, Science, Biotechnology, Virus, Cell, Cancer, Distinguishing, University, Biologic, Dove Medical Press, Neuroscience, UAB Hospital, Emory University, National academy, UAB, Glioblastoma, Radiation therapy, Neuro, Nature Biotechnology, Physician, Birmingham School of Law, Engineering, Neurosurgery, Potyvirus, Harvard Medical School, Supernova, Pulmonology, Hospital, Bangladesh Technical Education Board, University of Groningen, PNAS, Pharmaceutical industry

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.

Key Points: 
  • Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.
  • “Calidi continues to expand our Scientific and Medical Advisory Board, adding leading physicians and scientists from the top cancer hospitals and research institutions in the United States,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
  • Dr. Chiocca is a faculty member at Harvard Medical School and leads a laboratory focused on developing novel genetic therapies for malignant brain tumors.
  • from the University of Tennessee and completed his residency and fellowship at UAB Hospital in Neurology and Neuro-oncology.

University of Alabama at Birmingham Reaches 1,000 Patient Pulmonary Exams With Dynamic Digital Radiography

Retrieved on: 
Tuesday, March 7, 2023
Doctor of Philosophy, FCCP, Diaphragm, Radiological Society of North America, RSNA, Acquisition, Clinical research, RIS, COPD, Medicine, Hospital, COVID, Shimadzu, UAB Hospital, University, PACS, Annual general meeting, Roflumilast, McGough, Imaging, DDR, Assistant professor, Motion, University of Texas Health Science Center Department of Radiology, Patient, Lung, MD, Perfusion, Fluoroscopy, UAB, Workflow, Senior, Lung cancer, Kirklin Clinic, Medical imaging, Radiology

UAB Medicine is a leading lung transplant center and one of busiest in the US, with one-year patient and graft survival rates higher than national averages.

Key Points: 
  • UAB Medicine is a leading lung transplant center and one of busiest in the US, with one-year patient and graft survival rates higher than national averages.
  • DDR is a radiographic technique that provides a series of individual digital X-ray images acquired at high speed and low radiation dose.
  • These images provide diagnostic-quality views of anatomical structures in motion and the ability to visualize the dynamic interaction with physiological changes over time.
  • DDR enables efficient routine dynamic imaging, for example sniff tests of their transplant patients, without dedicated scheduling or disrupting the regular reading schedule.

Coave Therapeutics Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Next-generation Gene Therapies Targeting CNS Diseases

Retrieved on: 
Thursday, June 30, 2022
Central nervous system, Knowledge, Patient, Research, Harvard Medical School, Re Recher's Will Trusts, CNS, Degenerative disease, SAB, UPEC, University of Paris, Coronavirus Scientific Advisory Board (Turkey), Neurology, Doctor of Philosophy, UAB Hospital, Eye, Neurosurgery, Board, MD, Therapy, Neurodegeneration, Medical device, Vaccine, Management, Pharmaceutical industry, Hospital, Medicine, Neuroscience, Idinvest Partners, Genetics

PARIS, June 30, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, announces the formation of its Scientific Advisory Board (SAB) comprising international scientific and clinical experts in neurology and gene therapy.

Key Points: 
  • PARIS, June 30, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, announces the formation of its Scientific Advisory Board (SAB) comprising international scientific and clinical experts in neurology and gene therapy.
  • The newly formed SAB will provide Coave with expert guidance on its current and future research and development strategy, which includes a pipeline of next-generation gene therapy candidates targeting neurodegenerative diseases.
  • Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases.
  • Coave Therapeutics' next-generation AAV-Ligand Conjugate ('ALIGATER') platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases.

Coave Therapeutics Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Next-generation Gene Therapies Targeting CNS Diseases

Retrieved on: 
Thursday, June 30, 2022
Central nervous system, Knowledge, Patient, Research, Harvard Medical School, Re Recher's Will Trusts, CNS, Degenerative disease, SAB, UPEC, University of Paris, Coronavirus Scientific Advisory Board (Turkey), Neurology, Doctor of Philosophy, UAB Hospital, Eye, Neurosurgery, Board, MD, Therapy, Neurodegeneration, Medical device, Vaccine, Management, Pharmaceutical industry, Hospital, Medicine, Neuroscience, Idinvest Partners, Genetics

PARIS, June 30, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, announces the formation of its Scientific Advisory Board (SAB) comprising international scientific and clinical experts in neurology and gene therapy.

Key Points: 
  • PARIS, June 30, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, announces the formation of its Scientific Advisory Board (SAB) comprising international scientific and clinical experts in neurology and gene therapy.
  • The newly formed SAB will provide Coave with expert guidance on its current and future research and development strategy, which includes a pipeline of next-generation gene therapy candidates targeting neurodegenerative diseases.
  • Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases.
  • Coave Therapeutics' next-generation AAV-Ligand Conjugate ('ALIGATER') platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases.

Loopback Analytics and UAB Medicine Partner on Specialty Pharmacy Initiatives to Improve Patient Outcomes

Retrieved on: 
Tuesday, November 23, 2021
Patient, U.S. News & World Report Best Hospitals Rankings, University of Alabama System, Loopback, Bed, Hospital, News, Health, University of Alabama at Birmingham School of Medicine, University, Solution, Women's Choice Awards, Clinical and Translational Science Award, Center, School, Research, Birmingham, UAB, Academic health science centre, UAB Hospital, Associate, Multimedia, Medicine

DALLAS, Nov. 23, 2021 /PRNewswire/ -- Loopback Analytics, a leading provider of data-driven solutions for hospitals and health systems, is excited to announce it has partnered with UAB Medicine to continue advancing specialty pharmacy services.

Key Points: 
  • DALLAS, Nov. 23, 2021 /PRNewswire/ -- Loopback Analytics, a leading provider of data-driven solutions for hospitals and health systems, is excited to announce it has partnered with UAB Medicine to continue advancing specialty pharmacy services.
  • "We are excited for an opportunity to use advanced data analytics to build upon our patient-centered approach to delivering care," says Jennifer Peterson, Associate Chief Pharmacy Officer at UAB.
  • Specialty pharmacy is a rapidly evolving area in health care, and for academic medical centers like UAB Medicine, it's important for patients to get timely access to their medication and support for their outcomes.
  • "UAB Medicine is one of the top academic medical centers in the United States, and we are proud to accelerate their specialty pharmacy efforts with our advanced analytics solutions," said Neil Smiley, Loopback Analytics CEO.

Vickers joins Alabama Power board of directors

Retrieved on: 
Thursday, September 3, 2020
V-12 Navy College Training Program, States of the United States, University of Alabama School of Medicine, United States, Birmingham, Alabama, University of Alabama at Birmingham, University of Alabama, ALABAMA, Johns Hopkins School of Medicine, Johns Hopkins, Nancy E. Dunlap, UAB Hospital

BIRMINGHAM, Ala., Sept. 3, 2020 /PRNewswire/ -- Dr. Selwyn M. Vickers, senior vice president of medicine and dean of the University of Alabama School of Medicine at the University of Alabama at Birmingham (UAB), has been elected to the board of directors of Alabama Power.

Key Points: 
  • BIRMINGHAM, Ala., Sept. 3, 2020 /PRNewswire/ -- Dr. Selwyn M. Vickers, senior vice president of medicine and dean of the University of Alabama School of Medicine at the University of Alabama at Birmingham (UAB), has been elected to the board of directors of Alabama Power.
  • "I am honored to welcome Dr. Vickers to our board," said Mark Crosswhite, Alabama Power chairman, president and CEO.
  • Vickers serves as chair of UAB Medicine's Joint Operating Leadership Committee as well as the University of Alabama Health Services Foundation Board.
  • Vickers has served on the Johns Hopkins School of Medicine Board of Trustees and Johns Hopkins University Board of Trustees.